RRC ID 1400
著者 Kushida S, Peng BG, Uchimura E, Kuang M, Huang L, Miwa M, Ohno T.
タイトル A tumour vaccine of fixed tumour fragments in a controlled-release vehicle with cytokines for therapy of hepatoma in mice.
ジャーナル Dig Liver Dis
Abstract BACKGROUND:Cytokines can be strong potentiators for a tumour vaccine, but they have very short life in vivo when administered as a solution.
AIMS:To evaluate the slow release of interleukin 2 from a cytokine-vehicle in vitro and in vivo and to evaluate the anti-tumour activity of a new tumour vaccine in vivo.
METHODS:The tumour vaccine was composed of formalin-fixed Hepa 1-6 hepatoma tissue fragments, tuberculin and a lipid based vehicle containing granulocyte-macrophage colony-stimulating factor and interleukin 2. The quantity of interleukin 2 release from the cytokine-vehicle in vitro and in vivo was determined by a proliferation assay with CTLL-2 cell line. Hepa 1-6 hepatoma model system with C57BL/6J mice was used to examine protective and therapeutic anti-tumour effect of the vaccine.
RESULTS:Release of interleukin 2 from the cytokine-vehicle lasted 5 days in vitro and 3 days in vivo. The vaccine protected 67% of mice from a Hepa 1-6 cell challenge and had a therapeutic effect by prolonging the life span of mice bearing established Hepa 1-6 tumours of 5 mm in diameter. Of the treated mice, 20% became completely tumour-free.
CONCLUSIONS:Formalin-fixed tumour fragments and cytokines in controlled-release vehicle are useful in the rational design of tumour vaccines.
巻・号 36(7)
ページ 478-85
公開日 2004-7-1
DOI 10.1016/j.dld.2004.02.010
PII S1590-8658(04)00129-X
PMID 15285528
MeSH Animals Cancer Vaccines / administration & dosage* Delayed-Action Preparations Disease Models, Animal Interleukin-2 / administration & dosage* Liver Neoplasms, Experimental / prevention & control Liver Neoplasms, Experimental / therapy* Male Mice Mice, Inbred C57BL Pharmaceutical Vehicles
IF 3.57
引用数 2
WOS 分野 GASTROENTEROLOGY & HEPATOLOGY
リソース情報
ヒト・動物細胞 Hepa 1-6(RCB1638) CTLL-2(RCB0637)